Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Drug Name | CAB-AXL-ADC |
Trade Name | |
Synonyms | BA3011 |
Drug Descriptions |
CAB-AXL-ADC is an antibody-drug conjugate comprising a reversible Axl antibody conjugated to monomethyl auristatin E (MMAE), which delivers the cytotoxic agent to Axl-expressing tumor cells, potentially inducing cytotoxicity and tumor growth inhibition (Cancer Res 2018;78(13 Suppl):Abstract nr 827; Journal of Clinical Oncology 2018 36:15_suppl, TPS12126). |
DrugClasses | |
CAS Registry Number | NA |
NCIT ID | C156141 |
Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
---|---|---|---|
CAB-AXL-ADC | CAB-AXL-ADC | 0 | 2 |
CAB-AXL-ADC + unspecified PD-1 antibody | CAB-AXL-ADC unspecified PD-1 antibody | 0 | 1 |